Recordati Industria Chimica e Farmaceutica S.p.A. (RCDTF)
USD 56.04
(14.37%)
USD 56.04
(14.37%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 1.42 Billion EUR | 10.57% |
| 2022 | 1.28 Billion EUR | 11.65% |
| 2021 | 1.15 Billion EUR | 10.59% |
| 2020 | 1.04 Billion EUR | -0.28% |
| 2019 | 1.04 Billion EUR | 9.23% |
| 2018 | 956.66 Million EUR | 5.67% |
| 2017 | 905.36 Million EUR | 14.17% |
| 2016 | 792.98 Million EUR | 11.3% |
| 2015 | 712.46 Million EUR | 7.9% |
| 2014 | 660.3 Million EUR | 7.49% |
| 2013 | 614.3 Million EUR | 14.87% |
| 2012 | 534.76 Million EUR | 6.51% |
| 2011 | 502.05 Million EUR | 2.87% |
| 2010 | 488.06 Million EUR | -4.66% |
| 2009 | 511.9 Million EUR | 9.51% |
| 2008 | 467.43 Million EUR | 10.74% |
| 2007 | 422.08 Million EUR | 9.87% |
| 2006 | 384.17 Million EUR | 2.32% |
| 2005 | 375.45 Million EUR | 21.49% |
| 2004 | 309.03 Million EUR | 7.38% |
| 2003 | 287.78 Million EUR | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | 415.56 Million EUR | 16.42% |
| 2024 Q2 | 386.22 Million EUR | -7.06% |
| 2023 Q4 | 356.94 Million EUR | 7.07% |
| 2023 Q2 | 344.6 Million EUR | -11.12% |
| 2023 Q1 | 387.7 Million EUR | 16.84% |
| 2023 Q3 | 333.36 Million EUR | -3.26% |
| 2023 FY | 1.42 Billion EUR | 10.57% |
| 2022 Q3 | 330.12 Million EUR | 2.94% |
| 2022 FY | 1.28 Billion EUR | 11.65% |
| 2022 Q1 | 303.9 Million EUR | -1.7% |
| 2022 Q2 | 320.7 Million EUR | 5.53% |
| 2022 Q4 | 331.83 Million EUR | 0.52% |
| 2021 Q1 | 280.76 Million EUR | 9.48% |
| 2021 Q4 | 309.16 Million EUR | 11.09% |
| 2021 Q3 | 278.28 Million EUR | -2.05% |
| 2021 FY | 1.15 Billion EUR | 10.59% |
| 2021 Q2 | 284.12 Million EUR | 1.2% |
| 2020 Q4 | 256.45 Million EUR | 8.14% |
| 2020 FY | 1.04 Billion EUR | -0.28% |
| 2020 Q1 | 303.72 Million EUR | 11.01% |
| 2020 Q2 | 244.71 Million EUR | -19.43% |
| 2020 Q3 | 237.14 Million EUR | -3.09% |
| 2019 Q3 | 251.39 Million EUR | -0.8% |
| 2019 FY | 1.04 Billion EUR | 9.23% |
| 2019 Q4 | 273.59 Million EUR | 8.83% |
| 2019 Q1 | 266.52 Million EUR | 11.34% |
| 2019 Q2 | 253.43 Million EUR | -4.91% |
| 2018 FY | 956.66 Million EUR | 5.67% |
| 2018 Q4 | 239.37 Million EUR | 6.74% |
| 2018 Q3 | 224.25 Million EUR | -4.91% |
| 2018 Q2 | 235.82 Million EUR | -8.31% |
| 2018 Q1 | 257.21 Million EUR | 12.25% |
| 2017 Q1 | 236.13 Million EUR | 19.31% |
| 2017 Q2 | 217.99 Million EUR | -7.68% |
| 2017 Q3 | 222.1 Million EUR | 1.89% |
| 2017 FY | 905.36 Million EUR | 14.17% |
| 2017 Q4 | 229.13 Million EUR | 3.17% |
| 2016 Q4 | 197.91 Million EUR | 5.45% |
| 2016 Q1 | 208.54 Million EUR | 16.06% |
| 2016 Q2 | 198.84 Million EUR | -4.65% |
| 2016 Q3 | 187.67 Million EUR | -5.62% |
| 2016 FY | 792.98 Million EUR | 11.3% |
| 2015 Q4 | 179.68 Million EUR | 8.23% |
| 2015 Q1 | 187.45 Million EUR | 15.0% |
| 2015 Q2 | 179.31 Million EUR | -4.34% |
| 2015 Q3 | 166.01 Million EUR | -7.42% |
| 2015 FY | 712.46 Million EUR | 7.9% |
| 2014 FY | 660.3 Million EUR | 7.49% |
| 2014 Q2 | 163.21 Million EUR | -5.86% |
| 2014 Q4 | 162.99 Million EUR | 1.42% |
| 2014 Q3 | 160.72 Million EUR | -1.53% |
| 2014 Q1 | 173.36 Million EUR | 12.42% |
| 2013 Q4 | 154.2 Million EUR | 4.18% |
| 2013 Q2 | 152.85 Million EUR | -3.99% |
| 2013 Q1 | 159.21 Million EUR | 19.54% |
| 2013 FY | 614.3 Million EUR | 14.87% |
| 2013 Q3 | 148.02 Million EUR | -3.16% |
| 2012 Q1 | 141.56 Million EUR | 19.69% |
| 2012 Q2 | 130.86 Million EUR | -7.56% |
| 2012 Q3 | 129.14 Million EUR | -1.32% |
| 2012 Q4 | 133.19 Million EUR | 3.14% |
| 2012 FY | 534.76 Million EUR | 6.51% |
| 2011 Q4 | 118.27 Million EUR | 1.69% |
| 2011 FY | 502.05 Million EUR | 2.87% |
| 2011 Q1 | 130.93 Million EUR | 10.09% |
| 2011 Q2 | 136.54 Million EUR | 4.29% |
| 2011 Q3 | 116.3 Million EUR | -14.82% |
| 2010 Q4 | 118.93 Million EUR | 4.08% |
| 2010 Q2 | 128.71 Million EUR | 2.03% |
| 2010 FY | 488.06 Million EUR | -4.66% |
| 2010 Q3 | 114.26 Million EUR | -11.23% |
| 2010 Q1 | 126.15 Million EUR | -4.96% |
| 2009 FY | 511.9 Million EUR | 9.51% |
| 2009 Q1 | 123.52 Million EUR | 0.0% |
| 2009 Q2 | 134.51 Million EUR | 8.89% |
| 2009 Q4 | 132.74 Million EUR | 9.6% |
| 2009 Q3 | 121.11 Million EUR | -9.96% |
| 2008 FY | 467.43 Million EUR | 10.74% |
| 2007 FY | 422.08 Million EUR | 9.87% |
| 2006 FY | 384.17 Million EUR | 2.32% |
| 2005 FY | 375.45 Million EUR | 21.49% |
| 2004 FY | 309.03 Million EUR | 7.38% |
| 2003 FY | 287.78 Million EUR | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| AstraZeneca PLC | 34.69 Billion USD | 95.899% |
| Bristol-Myers Squibb Company PFD CONV 2 | 34.31 Billion USD | 95.854% |
| CSPC Pharmaceutical Group Limited | 30.13 Billion USD | 95.28% |
| Clarus Therapeutics Holdings, Inc. | 11.23 Million USD | -12560.176% |
| Novartis AG | 34.18 Billion USD | 95.839% |
| PT Kalbe Farma Tbk. | 743.47 Million USD | -91.348% |